Part I. Part I General Features of Brain Tumors. 1. Total Registered Number. 1) Number of Primary and Metastatic Brain Tumors

Transcript

1 1 General Features of Brain Tumors 1. Total Registered Number 1) Number of Primary and Metastatic Brain Tumors primary 3,491 3,593 3,530 3,673 4,108 4,400 3,998 4,302 metastatic ,221 4,309 4,260 4,423 4,959 5,355 4,879 5, primary 4,446 4,402 4,737 4,609 4,646 3,458 3,714 3,767 metastatic ,299 5,304 5,615 5,534 5,628 4,215 4,595 4, primary 3,407 68,281 metastatic ,563 4,325 82,844 2) Age Distribution of Primary Brain Tumors ( ) age male (%) female (%) (%) (0.6) 183 (0.5) 355 (0.5) (0.6) 133 (0.4) 320 (0.5) (0.5) 119 (0.3) 265 (0.4) (0.5) 123 (0.3) 265 (0.4) (0.6) 132 (0.4) 302 (0.5) (3.1) 732 (2.0) 1,657 (2.5) ,213 (4.0) 794 (2.1) 2,007 (3.0) ,230 (4.1) 980 (2.6) 2,210 (3.3) ,248 (4.1) 1,395 (3.7) 2,643 (3.9) ,312 (4.3) 1,572 (4.2) 2,884 (4.3) ,460 (4.8) 1,620 (4.3) 3,080 (4.6) ,942 (6.4) 2,003 (5.4) 3,945 (5.8) ,261 (7.5) 2,669 (7.1) 4,930 (7.3) ,600 (8.6) 3,528 (9.4) 6,128 (9.0) ,952 (9.7) 4,011 (10.7) 6,963 (10.3) ,156 (10.4) 4,169 (11.1) 7,325 (10.8) ,084 (10.2) 4,134 (11.0) 7,218 (10.7) ,741 (9.0) 3,999 (10.7) 6,740 (10.0) ,919 (6.3) 2,947 (7.9) 4,866 (7.2) ,036 (3.4) 1,561 (4.2) 2,597 (3.8) (1.1) 527 (1.4) 860 (1.3) (0.3) 108 (0.3) 184 (0.3) (0.0) 8 (0.0) 17 (0.0) ( - ) 3 (0.0) 3 (0.0) 30,314 (100.0) 37,450 (100.0) 67,764 (100.0)

2 2 3) Annual Trend of Frequency of Various Brain Tumors year meningioma * cases included for number ** malignant cases included % in all primary brain tumors in each year * pituitary neurinoma all glioma astrocytoma ** glioblastoma adenoma

3 3 4) Annual Trend of Frequency of Brain Tumors by Age Distribution * ( ) all primary brain tumor meningioma ** neurinoma **(schwannoma) astrocytoma ** glioblastoma , ,375 1,473 1, ,537 1,508 1,848 1, ,870 1,700 1,832 1, ,024 1,859 1,928 1, ,753 1,885 1,987 1, ,454 1,654 2,040 1, ,164 1,088 1,391 1, ,229 16,984 18,305 14,246 4,587 4,405 4,956 3,864 1,727 1,829 1,864 1,455 2,433 2,067 1,893 1,350 1,592 1,496 1,594 1, * cases included ** malignant cases included

4 4 2. Resident Area & Birth Place: All Primary Brain Tumors prefecture residence birthplace prefecture residence birthplace 01 Hokkaido 2, Osaka 6, Aomori Hyogo 3, Iwate Nara 1, Miyagi 1, Wakayama 1, Akita Tottori Yamagata Shimane Fukusima 1, Okayama Ibaraki 1, Hiroshima 1, Tochigi 1, Yamaguchi 1, Gunma 1, Tokushima Saitama 2, Kagawa Chiba 1, Ehime 1, Tokyo 5,764 1, Kochi Kanagawa 3, Fukuoka 2, Niigata 2,133 1, Saga Toyama Nagasaki Ishikawa 1, Kumamoto 1, Fukui Oita 1, Yamanashi Miyazaki 1, Nagano Kagoshima Gifu 1, Okinawa Shizuoka 1, foreign country Aichi 2, ,192 48, Mie 1, Shiga Kyoto 1, ,281 68,281

5 5 3. Frequency of Primary Brain Tumors Frequency of Tumors by Histology ( ) histology number % ganglioglioma anaplastic gangliglioma sympathicoblastoma neuroblastoma medulloepithelioma neuroepithelioma polar spongioblastoma astrocytoma 4, anaplastic astrocytoma 3, oligodendroglioma anaplastic oligodendroglioma mixed glioma ependymoma anaplastic ependymoma plexus papilloma malignant plexus papilloma glioblastoma 6, medulloblastoma neurinoma 6, von Recklinghausen's disease malignant neurinoma(schwannoma) meningioma 17, malignant meningioma hemangioblastoma 1, hemangiopericytoma germinoma 1, pineocytoma pineoblastoma pituitary adenoma * 2, non-functioning pituitary adenoma 4, HGH producing pituitary adenoma 2, PRL producing pituitary adenoma 2, ACTH producing pituitary adenoma other functioning pituitary adenoma malignant pituitary adenoma craniopharyngioma 2, glioma of pituitary region teratoma malignant teratoma choriocarcinoma embryonal carcinoma yolk sac tumor other germ cell tumor dermoid epidermoid chordoma malignant chordoma tumor of bone and cartilage lipoma malignant lymphoma 2, other sarcoma primary malignant melanoma glioma ** multiple others 1, unclassified tumor , unkown 1,790 * number of the pituitary adenoma by classic classification ** not verified in detail

6 6 4. Age Distribution of Various Brain Tumors ( ) sympathicoblastoma ganglioglioma malignant gangliglioma age and paraganglioma neuroblastoma medulloepithelioma m f (%) m f (%) m f (%) m f (%) m f (%) (2.7) (-) (-) (6.3) (-) (2.3) (4.3) 1-1 (4.2) (3.2) 1-1 (7.7) (1.5) (-) (-) (-) (-) (-) (-) (-) (2.1) 1-1 (7.7) (1.1) (6.4) (-) (4.2) (-) (8.8) (8.5) (-) (11.6) 1-1 (7.7) (11.0) 1-1 (2.1) (-) (4.2) (15.4) (14.5) (8.5) (-) (5.3) (7.7) (12.2) (6.4) (4.2) 1-1 (1.1) (7.7) (11.0) (-) (-) (7.4) (-) (6.8) (6.4) 1-1 (4.2) 3-3 (3.2) (-) (4.6) (6.4) (-) (6.3) 1-1 (7.7) (3.8) 1-1 (2.1) (16.7) (6.3) 1-1 (7.7) (5.7) (14.9) (16.7) (7.4) (7.7) (2.7) (4.6) (20.8) (6.3) 1-1 (7.7) (4.2) (8.5) 2-2 (8.3) (9.5) 1-1 (7.7) (2.3) (6.4) (16.7) (8.4) 1-1 (7.7) (2.7) (4.3) (4.2) (5.3) (-) (1.5) (6.4) (-) (-) (-) (0.4) (4.3) (4.2) 1-1 (1.1) (-) (0.4) (-) (-) (1.1) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (100.0) (100.0) (100.0) (100.0) (100.0) m:male, f:female age neuroepithelionma polar spongioblastoma astrocytoma anaplastic astrocytoma m f (%) m f (%) m f (%) m f (%) (-) 1-1 (1.9) (0.9) (0.5) (-) (-) (1.2) (0.4) (-) (5.8) (1.2) (0.4) (-) (5.8) (1.3) (0.2) (-) (5.8) (1.5) (0.3) (10.0) (19.2) (6.6) (3.5) (5.0) (13.5) (7.0) (3.3) (-) (15.4) (6.0) (2.5) (15.0) 1-1 (1.9) (5.9) (2.9) (10.0) 1-1 (1.9) (6.8) (4.6) (-) (5.8) (7.5) (5.8) (-) (7.7) (8.6) (7.3) (15.0) (-) (9.0) (7.4) (10.0) 1-1 (1.9) (7.5) (8.7) (10.0) 1-1 (1.9) (6.8) (9.1) (10.0) 2-2 (3.9) (6.3) (9.9) (5.0) (5.8) (5.1) (10.3) (5.0) (-) (4.8) (9.0) (-) (1.9) (3.2) (7.8) (5.0) (-) (2.2) (4.3) (-) (-) (0.6) (1.7) (-) (-) (0.1) (0.2) (-) (-) (-) (-) (-) (-) (-) (-) (100.0) (100.0) 2,522 2,143 4,665 (100.0) 1,731 1,347 3,078 (100.0)

7 7 anaplastic oligodendroglioma age oligodendroglioma mixed glioma ependymoma m f (%) m f (%) m f (%) m f (%) (0.2) (-) (0.3) (2.4) (-) (-) (-) (6.3) (0.3) (-) (1.2) (5.4) (0.2) (-) (1.2) (4.6) (0.2) (-) (0.3) (3.0) (1.8) 1-1 (0.6) (3.3) (13.2) (3.8) 2-2 (1.2) (2.1) (6.9) (4.0) (1.2) 6-6 (1.8) (7.4) (4.1) (3.7) (4.2) (7.1) (7.3) (1.9) (4.8) (4.6) (8.8) (5.0) (8.1) (2.8) (9.2) (7.5) (9.9) (6.1) (13.5) (9.9) (14.7) (6.3) (11.7) (13.7) (12.6) (5.4) (12.4) (11.8) (10.2) (5.4) (7.3) (11.2) (12.3) (3.7) (6.8) (14.3) (5.4) (5.0) (4.5) (8.1) (4.5) (3.0) (3.0) (8.7) (1.8) (0.6) (1.2) 2-2 (1.2) (0.9) (0.9) (-) (-) (0.6) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (100.0) (100.0) (100.0) (100.0) anaplastic malignant plexus plexus papilloma age ependymoma papilloma glioblastoma m f (%) m f (%) m f (%) m f (%) (12.3) (22.4) (20.0) (0.2) (9.8) (5.6) 4-4 (13.3) (0.1) (8.0) (3.4) 2-2 (6.7) (0.2) (3.7) (5.6) (10.0) (0.2) (5.5) 1-1 (0.6) (-) (0.2) (9.2) (5.0) (-) (1.1) (9.2) 2-2 (1.1) (6.7) (1.2) (3.1) (1.7) (-) (1.4) (3.7) (7.8) (3.3) (1.7) (3.1) (4.5) (-) (2.1) (3.1) (5.6) (13.3) (2.7) (4.3) (3.9) (-) (3.9) (3.1) (5.0) (-) (5.2) (5.5) (5.6) (3.3) (6.8) (3.1) (2.8) (10.0) (9.8) (2.5) (8.9) (6.7) (12.5) (4.9) (3.4) 1-1 (3.3) (14.7) (3.7) (2.8) (-) (14.3) (1.8) (2.8) 1-1 (3.3) (12.4) (0.6) (0.6) (-) (6.6) (-) 1-1 (0.6) (-) (2.4) (-) (0.6) (-) (0.5) (-) (-) (-) 2-2 (0.0) (-) (-) (-) (-) (100.0) (100.0) (100.0) 3,576 2,450 6,026 (100.0)

8 8 neurinoma malignant neurinoma medulloblastoma neurofibromatosis age (schwannoma) (schwannoma) m f (%) m f (%) m f (%) m f (%) (4.8) (0.0) (0.6) (-) (9.4) (-) (1.1) (-) (5.7) (-) (-) (-) (4.5) (0.0) (-) (-) (7.0) (-) (1.1) (-) (32.8) (0.2) (6.2) (-) (20.0) (0.4) (9.5) 1-1 (3.6) (6.2) (1.2) (14.0) (-) (3.3) (2.3) (12.3) (-) (2.6) (3.4) (8.4) (3.6) (0.9) (4.5) (7.3) (3.6) (1.0) (6.3) (6.2) (10.7) (0.7) (9.2) (4.5) 1-1 (3.6) (0.4) (11.9) (8.9) (14.3) (0.4) ,014 (14.8) (7.8) (7.1) (-) (14.5) (4.5) (14.3) (-) (12.9) (2.8) (21.4) (-) (9.9) (1.7) 1-1 (3.6) (0.3) (5.6) (2.2) (3.6) (-) (2.2) (0.6) (7.1) (0.1) (0.5) (-) (3.6) (-) (0.1) 1-1 (0.6) (-) (-) (-) (-) (-) (-) (-) (-) (-) (100.0) 2,938 3,909 6,847 (100.0) (100.0) (100.0) age meningioma malignant meningioma hemangioblastoma hemangiopericytoma m f (%) m f (%) m f (%) m f (%) (0.1) (0.3) (0.3) 1-1 (0.7) (0.0) (-) 1-1 (0.1) (-) (0.0) (-) (-) (-) (0.0) 1-1 (0.3) (-) (-) (0.0) 1-1 (0.3) 1-1 (0.1) (-) (0.2) (0.8) (0.3) (2.0) (0.3) 2-2 (0.6) (1.5) (1.3) (0.4) (1.1) (4.3) (4.6) (0.8) (1.7) (5.9) (7.1) (1.2) (1.9) (7.4) (9.7) (2.0) (2.5) (8.0) (6.5) (3.9) (4.4) (8.9) (5.2) ,124 (6.4) (6.9) (9.4) (6.5) ,318 1,748 (10.0) (8.5) (10.8) (14.9) ,653 2,194 (12.6) (8.5) (11.0) (7.8) ,806 2,426 (13.9) (9.9) (9.7) (10.4) ,819 2,478 (14.2) (12.6) (8.4) (5.8) ,890 2,559 (14.7) (13.2) (6.8) (9.7) ,440 1,934 (11.1) (12.4) (5.2) (2.6) ,060 (6.1) (8.8) (1.8) (3.9) (1.9) (4.1) (0.4) (1.3) (0.4) 4-4 (1.1) (0.2) (-) (0.0) 1-1 (0.3) (-) (-) (0.0) (-) (-) (-) 4,691 12,757 17,448 (100.0) (100.0) ,126 (100.0) (100.0)

9 9 age germinoma pineocytoma pineoblastoma pituitary adenoma m f (%) m f (%) m f (%) m f (%) (0.2) (0.8) (6.5) (0.0) (0.2) (-) 5-5 (6.5) 1-1 (0.0) (0.1) (-) (3.9) (-) (0.1) (-) (5.2) (-) (0.2) (-) (-) (-) (7.6) (2.5) (7.8) (0.1) (28.7) (5.8) (10.4) (0.9) (27.2) (9.2) (6.5) (2.7) (17.7) (10.0) (7.8) (5.8) (8.2) (6.7) (5.2) (5.7) (3.8) (6.7) 4-4 (5.2) (6.0) (2.1) (8.3) (7.8) (7.9) (1.4) (8.3) (5.2) (9.7) (1.3) (8.3) (6.5) (11.6) (0.2) (13.3) (3.9) (11.4) (0.3) (5.0) (3.9) (10.8) (0.5) (9.2) (2.6) (9.9) (0.2) (5.0) (1.3) (8.7) (-) (-) (1.3) (5.4) (0.1) (-) (-) (2.7) (-) 1-1 (0.8) (2.6) (0.5) (-) (-) (-) (0.1) (-) (-) (-) (-) (-) (-) (-) (-) ,246 (100.0) (100.0) (100.0) 1,107 1,411 2,518 (100.0) *pituitary adenoma by classic classification age Non-functioning p. ad. HGH producing p. ad. PRL producing p. ad. ACTH producing p. ad. other functioning p. ad. m f (%) m f (%) m f (%) m f (%) m f (%) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (0.0) 1-1 (0.1) (-) (-) (-) (-) (-) (-) (-) (-) (0.0) (0.2) (0.0) (0.6) 1-1 (0.5) (0.5) (0.7) (1.0) (1.7) 1-1 (0.5) (1.9) (1.8) (8.1) (4.6) (3.9) (2.7) (3.9) (19.0) (6.4) (3.4) (3.4) (6.0) (20.4) (9.9) (8.3) (3.9) (7.8) (13.3) (10.8) (9.3) (5.5) (11.1) (9.7) (11.7) (6.4) (7.9) (11.2) (8.1) (13.4) (11.8) (10.4) (15.0) (5.8) (11.2) (10.8) (12.0) (15.1) (4.7) (8.4) (9.3) (14.0) (10.2) (3.6) (9.5) (12.8) (13.8) (8.4) (2.7) (5.5) (11.3) (12.1) (5.1) (2.4) (3.1) (6.4) (8.1) (2.4) (0.6) (2.6) (2.9) (3.1) (0.8) (0.3) (0.6) (1.5) (0.7) (0.1) (0.2) (-) (1.0) (0.1) 1-1 (0.1) (-) (-) (-) (0.0) (-) (-) (-) (-) (-) (-) (-) (-) (-) 2,125 2,173 4,298 (100.0) 980 1,048 2,028 (100.0) 644 1,698 2,342 (100.0) (100.0) (100.0)

10 10 age malignant pituitary glioma of pituitary region craniopharyngioma adenoma or neurohypophysis teratoma m f (%) m f (%) m f (%) m f (%) (-) (0.5) (8.3) (6.0) (-) (0.4) (-) 2-2 (1.7) (-) (0.6) (-) 2-2 (1.7) (-) (1.0) (-) 1-1 (0.9) (-) (1.6) (-) 4-4 (3.5) (6.3) (7.3) (16.7) (18.1) (-) (7.4) (-) (18.1) (6.3) (5.0) (16.7) (18.1) (-) (5.4) (-) (6.9) (6.3) (4.8) (-) (3.5) (12.5) (5.4) (-) (3.5) (6.3) (6.9) 1-1 (8.3) 4-4 (3.5) (-) (7.2) (-) (1.7) (-) (8.9) (16.7) 1-1 (0.9) (25.0) (8.0) (8.3) (2.6) (6.3) (9.4) 2-2 (16.7) (1.7) (12.5) (7.3) (-) (3.5) (12.5) (7.1) 1-1 (8.3) (2.6) (6.3) (3.8) (-) (0.9) (-) (1.5) (-) (-) (-) (0.5) (-) 1-1 (0.9) (-) (0.1) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (100.0) 1,180 1,160 2,340 (100.0) (100.0) (100.0) age malignant teratoma choriocarcinoma embryonal carcinoma yolk sac tumor other germ cell tumor m f (%) m f (%) m f (%) m f (%) m f (%) (6.4) (-) (-) (3.5) (1.3) (-) (-) (1.6) (-) (-) (1.8) (-) 1-1 (1.6) (-) 1-1 (0.7) (1.8) (-) (1.6) 1-1 (1.7) (-) (3.6) (3.6) (-) (-) 1-1 (0.7) (28.2) (16.4) (10.9) (10.3) (15.4) (23.6) (40.0) (32.8) (29.3) (30.2) (16.4) (21.8) (23.4) (29.3) (25.5) (10.0) (9.1) (15.6) 8-8 (13.8) (14.8) (2.7) (-) 3-3 (4.7) (1.7) (4.0) (-) (3.6) 1-1 (1.6) (5.2) (1.3) (0.9) (-) (-) 1-1 (1.7) 1-1 (0.7) (1.8) (-) 1-1 (1.6) (-) (1.3) (0.9) (-) (0) 1-1 (1.7) 2-2 (1.3) (0.9) (3.6) 1-1 (1.6) (-) 1-1 (0.7) (0.9) 1-1 (1.8) (-) (-) (2.0) (-) (-) 1-1 (1.6) (-) (-) (-) (-) (1.6) 1-1 (1.7) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (100.0) (100.0) (100.0) (100.0) (100.0)

11 11 age dermoid epidermoid chordoma malignant chordoma tumor of bone and cartilage m f (%) m f (%) m f (%) m f (%) m f (%) (7.4) (0.7) (0.3) (-) (1.4) (5.4) (0.5) (-) (-) 3-3 (1.1) (2.7) (0.2) (0.3) (-) (1.4) (0.7) (0.2) (-) (-) (1.1) (0.7) (0.4) (-) (-) 2-2 (0.7) (3.4) (1.0) (1.7) (-) (8.5) (5.4) (1.3) (2.3) (-) (8.5) (6.1) (2.4) (5.6) 1-1 (12.5) (8.8) (7.4) (2.8) (4.3) (-) (8.8) (5.4) (7.4) (6.6) 1-1 (12.5) (5.3) (7.4) (6.2) (6.6) (-) (7.4) (6.1) (12.0) (6.6) (12.5) (7.8) (4.7) (11.9) (6.3) 1-1 (12.5) (4.6) (7.4) (13.7) (8.3) (-) (7.8) (9.5) (11.7) (11.3) 1-1 (12.5) (6.7) (6.8) (10.4) (10.6) (-) (6.0) (6.1) (8.1) (10.3) (-) (5.6) (2.7) (5.4) (11.3) (37.5) (4.9) (2.7) (2.2) (4.6) (-) (2.8) (2.0) (1.3) (2.0) (-) (0.7) (-) (0.2) (0.7) (-) (0.4) (-) (-) (0.3) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) (100.0) (100.0) (100.0) (100.0) (100.0) primary malignant lipoma malignant lymphoma other sarcoma age melanoma glioma * m f (%) m f (%) m f (%) m f (%) m f (%) (6.0) 1-1 (0.1) (1.4) (-) (1.0) (1.5) (-) 1-1 (0.7) (-) (1.9) (-) 1-1 (0.1) (1.4) (-) (1.5) (0.8) (0.1) 1-1 (0.7) (-) (2.1) (0.8) (0.1) 2-2 (1.4) (-) (4.4) (6.0) (0.2) (6.4) 1-1 (2.0) (19.4) (6.0) (0.4) (7.1) 1-1 (2.0) (10.4) (5.3) (0.5) (8.5) (-) (5.2) (8.3) (0.6) (9.9) (5.9) (4.6) (4.5) (1.5) (7.1) (3.9) (4.4) (6.0) (1.2) (5.0) 1-1 (2.0) (4.0) (10.5) (2.8) (3.6) (3.9) (4.2) (8.3) (4.3) (5.7) 6-6 (11.8) (6.0) (5.3) (5.3) (4.3) (13.7) (4.8) (6.8) (8.7) (8.5) (13.7) (4.6) (5.3) (12.6) (4.3) (13.7) (3.3) (4.5) (16.9) (5.7) (7.8) (3.5) (9.8) (16.8) (9.2) (9.8) (6.5) (3.8) (14.4) (4.3) 1-1 (2.0) (3.1) (0.8) (9.2) (3.6) (7.8) (3.5) (-) (3.4) (1.4) (-) (1.5) (-) (1.0) (-) (-) (-) (-) (0.1) (-) (-) (0.2) (-) (-) (-) (-) (-) (100.0) 1, ,035 (100.0) (100.0) (100.0) (100.0) * glioma, not verified in detail

12 12 age multiple others unclassified tumor m f (%) m f (%) m f (%) m f (%) m f (%) (-) (2.2) (5.0) (0.5) (0.6) (-) (1.4) (2.5) (0.5) (0.9) (-) (1.3) (0.5) (0.4) (0.7) (-) (1.3) (1.0) (0.4) (0.7) (2.2) (1.2) (1.0) (0.4) (0.6) (6.5) (4.0) (4.5) ,570 (2.4) (4.9) (4.4) (5.6) (5.0) 1, ,916 (2.9) (5.2) (6.5) (6.6) (7.5) 1, ,120 (3.2) (5.1) (4.4) (6.5) (7.5) 1,208 1,355 2,563 (3.9) (4.5) (6.5) (6.7) (4.5) 1,273 1,548 2,821 (4.3) (3.6) (2.2) (7.4) (5.0) 1,417 1,578 2,995 (4.5) (4.8) (4.4) (7.5) (4.5) 1,901 1,965 3,866 (5.9) (4.5) (13.0) (7.0) (8.5) 2,214 2,619 4,833 (7.3) (5.5) (10.9) (7.7) (5.5) 2,543 3,458 6,001 (9.1) (7.2) (8.7) (8.2) (7.5) 2,896 3,950 6,846 (10.4) (6.6) (6.5) (7.5) (8.0) 3,091 4,114 7,205 (10.9) (6.8) (6.5) (6.1) (7.5) 3,023 4,046 7,069 (10.7) (8.4) (13.0) (6.1) (8.5) 2,660 3,933 6,593 (10.0) (8.3) (2.2) (3.4) (1.5) 1,860 2,854 4,714 (7.1) (8.6) (2.2) (1.8) (4.0) 978 1,504 2,482 (3.8) (6.5) (-) (0.4) 2-2 (1.0) (1.2) (4.1) (-) (0.1) (-) (0.2) (1.6) (-) (0.1) (-) (0.0) (0.2) (-) (0.1) (-) (0.0) (-) (100.0) ,889 (100.0) (100.0) 29,427 36,571 65,998 (100.0) ,765 (100.0)

13 13 5. Age Distribution of Brain Tumors by Sites ( ) 1) All Primary Brain Tumors : Supra or Infratentorial age supra- infrasupra- and infra others (1.6) 649 (4.4) 58 (2.7) 1,403 (2.3) 98 (1.8) 6 (1.3) (1.7) 703 (4.8) 53 (2.5) 1,536 (2.5) 113 (2.0) 8 (1.7) ,273 (2.8) 489 (3.3) 77 (3.6) 1,839 (3.0) 159 (2.8) 9 (1.9) ,463 (3.3) 361 (2.5) 104 (4.9) 1,928 (3.1) 265 (4.7) 17 (3.6) ,736 (3.9) 428 (2.9) 78 (3.7) 2,242 (3.6) 376 (6.7) 25 (5.3) ,855 (4.1) 535 (3.7) 80 (3.8) 2,470 (4.0) 388 (6.9) 26 (5.5) ,005 (4.5) 588 (4.0) 80 (3.8) 2,673 (4.3) 383 (6.8) 24 (5.1) ,545 (5.7) 822 (5.6) 120 (5.7) 3,487 (5.7) 423 (7.6) 35 (7.4) ,195 (7.1) 1,075 (7.4) 148 (7.0) 4,418 (7.2) 472 (8.4) 40 (8.5) ,894 (8.7) 1,414 (9.7) 217 (10.2) 5,525 (9.0) 560 (10.0) 43 (9.1) ,497 (10.0) 1,678 (11.5) 210 (9.9) 6,385 (10.4) 540 (9.7) 38 (8.1) ,883 (10.9) 1,653 (11.3) 250 (11.8) 6,786 (11.0) 483 (8.6) 56 (11.9) ,963 (11.0) 1,518 (10.4) 204 (9.6) 6,685 (10.8) 492 (8.8) 41 (8.7) ,751 (10.6) 1,301 (8.9) 223 (10.5) 6,275 (10.2) 418 (7.5) 47 (10.0) 70-6,410 (14.3) 1,414 (9.7) 221 (10.4) 8,045 (13.0) 426 (7.6) 56 (11.9) 44,946 (100.0) 14,628 (100.0) 2,123 (100.0) 61,697 (100.0) 5,596 (100.0) 471 (100.0) ) All Glioma age supra- infrasupra- and infra others (2.6) 529 (20.2) 28 (11.0) 922 (5.5) 10 (6.0) 4 (4.3) (2.1) 543 (20.7) 19 (7.5) 859 (5.1) 19 (11.4) 3 (3.2) (2.8) 342 (13.1) 18 (7.1) 753 (4.5) 15 (9.0) 4 (4.3) (3.0) 168 (6.4) 23 (9.0) 606 (3.6) 13 (7.8) 3 (3.2) (3.5) 127 (4.9) 17 (6.7) 629 (3.8) 9 (5.4) 2 (2.1) (4.4) 109 (4.2) 12 (4.7) 728 (4.4) 11 (6.6) 3 (3.2) (5.2) 87 (3.3) 13 (5.1) 826 (4.9) 15 (9.0) 3 (3.2) (6.6) 103 (3.9) 13 (5.1) 1,027 (6.1) 9 (5.4) 4 (4.3) ,066 (7.7) 84 (3.2) 13 (5.1) 1,163 (7.0) 8 (4.8) 13 (13.8) ,120 (8.1) 91 (3.5) 19 (7.5) 1,230 (7.4) 14 (8.4) 7 (7.5) ,266 (9.1) 77 (2.9) 15 (5.9) 1,358 (8.1) 15 (9.0) 8 (8.5) ,386 (10.0) 101 (3.9) 16 (6.3) 1,503 (9.0) 11 (6.6) 12 (12.8) ,493 (10.8) 73 (2.8) 14 (5.5) 1,580 (9.4) 8 (4.8) 3 (3.2) ,346 (9.7) 79 (3.0) 18 (7.1) 1,443 (8.6) 5 (3.0) 13 (13.8) 70-1,988 (14.3) 107 (4.1) 17 (6.7) 2,112 (12.6) 5 (3.0) 12 (12.8) 13,864 (100.0) 2,620 (100.0) 255 (100.0) 16,739 (100.0) 167 (100.0) 94 (100.0)

14 14 3) All Primary Brain Tumors : Central or Lateral age right left right and left central others (1.4) 264 (1.3) 146 (2.8) 747 (3.9) 1,428 (2.2) 59 (1.8) 20 (2.7) (1.2) 283 (1.4) 122 (2.4) 946 (4.9) 1,592 (2.5) 48 (1.5) 17 (2.3) (1.8) 339 (1.7) 147 (2.9) 1,084 (5.6) 1,912 (3.0) 78 (2.4) 17 (2.3) (1.9) 380 (1.9) 172 (3.3) 1,124 (5.8) 2,048 (3.2) 124 (3.8) 38 (5.2) (2.4) 461 (2.3) 173 (3.4) 1,296 (6.7) 2,392 (3.8) 224 (6.8) 27 (3.7) (3.1) 598 (3.0) 198 (3.9) 1,218 (6.3) 2,628 (4.1) 226 (6.9) 30 (4.1) (3.7) 767 (3.9) 191 (3.7) 1,148 (6.0) 2,827 (4.4) 216 (6.5) 37 (5.1) ,054 (5.4) 1,072 (5.4) 296 (5.8) 1,244 (6.5) 3,666 (5.8) 232 (7.0) 47 (6.4) ,388 (7.1) 1,473 (7.5) 328 (6.4) 1,412 (7.3) 4,601 (7.2) 273 (8.3) 56 (7.7) ,870 (9.6) 1,817 (9.2) 440 (8.6) 1,613 (8.4) 5,740 (9.0) 331 (10.0) 57 (7.8) ,219 (11.4) 2,195 (11.1) 476 (9.2) 1,657 (8.6) 6,547 (10.3) 351 (10.6) 65 (8.9) ,290 (11.7) 2,415 (12.2) 586 (11.4) 1,649 (8.6) 6,940 (10.9) 304 (9.2) 81 (11.1) ,393 (12.2) 2,324 (11.8) 609 (11.8) 1,534 (8.0) 6,860 (10.8) 276 (8.4) 82 (11.2) ,276 (11.6) 2,261 (11.5) 561 (10.9) 1,315 (6.8) 6,413 (10.1) 274 (8.3) 53 (7.3) ,037 (15.5) 3,097 (15.7) 704 (13.7) 1,301 (6.8) 8,139 (12.8) 285 (8.6) 103 (14.1) 19,550 (100.0) 19,746 (100.0) 5,149 (100.0) 19,288 (100.0) 63,733 (100.0) 3,301 (100.0) 730 (100.0) General Features of Brain Tumors in Children : Age ) Frequency of Primary Brain Tumors by Histology ( ) histology number % histology number % glioblastoma nonfuctioning pituitary adenoma anaplastic ganglioglioma HGH producing pituitary adenoma sympathicoblastoma PRL producing pituitary adenoma neuroblastoma ACTH producing pituitary adenoma medulloepithelioma other functioning pituitary adenoma neuroepithelioma malignant pituitary adenoma polar spongioblastoma craniopharyngioma astrocytoma glioma of pituitary region anaplastic astrocytoma teranoma oligodendroglioma malignant teranoma malignant oligodendroblastoma choriocarcinoma mixed glioma embryonal carcinoma ependymoma yolk sac tumor anaplastic ependymoma other germ cell tumor plexus papilloma dermoid malignant plexus papilloma epidermoid glioblastoma chordoma medulloblastoma malignant chordoma - (-) neurinoma (schwannoma) tumor of bone and cartilage von Recklinghausen's disease lipoma malignant neurinoma (schwannoma) malignant lymphoma meningioma other sarcoma malignant meningiona primary malignant melanoma hemangioblastoma glioma ** hemangiopericytoma multiple germinoma others pineocytoma unclassified tumor pineoblastoma , pituitary adenoma * * number of the pituitary adenoma by classic classification ** glioma, not verified

15 15 2) Age and Sex Distribution of Primary Brain Tumors in Children ( ) age male (%) female (%) (%) <1 172 (5.8) 183 (8.3) 355 (6.9) (6.3) 133 (6.0) 320 (6.2) (4.9) 119 (5.4) 265 (5.1) (4.8) 123 (5.6) 265 (5.1) (5.8) 132 (6.0) 302 (5.8) (6.5) 149 (6.7) 340 (6.6) (5.4) 143 (6.5) 302 (5.8) (5.6) 136 (6.1) 302 (5.8) (6.6) 160 (7.2) 356 (6.9) (7.2) 144 (6.5) 357 (6.9) (7.5) 141 (6.4) 362 (7.0) (7.0) 139 (6.3) 346 (6.7) (8.1) 178 (8.0) 416 (8.0) (9.2) 163 (7.4) 434 (8.4) (9.3) 173 (7.8) 449 (8.7) 2,955 (100.0) 2,216 (100.0) 5,171 (100.0) 3) Age Distribution of Supra or Infratentorial Tumors in Children ( ) supra - and age supra- infra- infra others <1 199 (7.2) 96 (5.2) 23 (12.2) 318 (6.7) 37 (10.0) - (-) (4.3) 170 (9.2) 12 (6.4) 301 (6.3) 19 (5.1) - (-) (4.4) 120 (6.5) 11 (5.9) 252 (5.3) 12 (3.2) 1 (4.3) (4.6) 113 (6.1) 6 (3.2) 245 (5.1) 17 (4.6) 3 (13.0) (4.8) 150 (8.1) 6 (3.2) 287 (6.0) 13 (3.5) 2 (8.7) (5.4) 155 (8.4) 16 (8.5) 320 (6.7) 18 (4.9) 2 (8.7) (5.0) 145 (7.9) 4 (2.1) 286 (6.0) 13 (3.5) 3 (13.0) (4.4) 148 (8.0) 12 (6.4) 280 (5.9) 20 (5.4) 2 (8.7) (6.6) 136 (7.4) 12 (6.4) 329 (6.9) 26 (7.0) 1 (4.3) (7.0) 119 (6.5) 9 (4.8) 321 (6.7) 36 (9.7) - (-) (7.3) 120 (6.5) 10 (5.3) 332 (6.9) 28 (7.6) 2 (8.7) (7.9) 91 (4.9) 13 (6.9) 321 (6.7) 23 (6.2) 2 (8.7) (10.1) 95 (5.2) 15 (8.0) 388 (8.1) 28 (7.6) - (-) (10.8) 85 (4.6) 19 (10.1) 401 (8.4) 29 (7.8) 4 (17.4) (10.1) 98 (5.3) 20 (10.6) 397 (8.3) 51 (13.8) 1 (4.3) 2,749 (100.0) 1,841 (100.0) 188 (100.0) 4,778 (100.0) 370 (100.0) 23 (100.0) 4) Age Distribution of Tumors in Children by sites : Central or Lateral ( ) age right left right and left central others <1 68 (8.0) 76 (8.6) 43 (10.4) 147 (5.3) 334 (6.8) 18 (9.7) 3 (5.6) 1 54 (6.3) 44 (5.0) 34 (8.2) 170 (6.1) 302 (6.1) 14 (7.6) 4 (7.4) 2 59 (6.9) 46 (5.2) 27 (6.5) 119 (4.3) 251 (5.1) 10 (5.4) 4 (7.4) 3 54 (6.3) 48 (5.4) 21 (5.1) 127 (4.6) 250 (5.1) 9 (4.9) 6 (11.1) 4 36 (4.2) 50 (5.6) 21 (5.1) 184 (6.6) 291 (5.9) 8 (4.3) 3 (5.6) 5 48 (5.6) 61 (6.9) 33 (8.0) 183 (6.6) 325 (6.6) 11 (5.9) 4 (7.4) 6 39 (4.6) 54 (6.1) 20 (4.8) 176 (6.3) 289 (5.9) 9 (4.9) 4 (7.4) 7 33 (3.9) 36 (4.1) 26 (6.3) 193 (6.9) 288 (5.8) 11 (5.9) 3 (5.6) 8 61 (7.1) 66 (7.4) 21 (5.1) 200 (7.2) 348 (7.1) 5 (2.7) 3 (5.6) 9 60 (7.0) 66 (7.4) 22 (5.3) 194 (7.0) 342 (6.9) 12 (6.5) 3 (5.6) (6.1) 71 (8.0) 19 (4.6) 208 (7.5) 350 (7.1) 8 (4.3) 4 (7.4) (7.1) 54 (6.1) 30 (7.2) 183 (6.6) 328 (6.7) 11 (5.9) 7 (13.0) (9.1) 73 (8.2) 34 (8.2) 208 (7.5) 393 (8.0) 22 (11.9) 1 (1.9) (9.4) 65 (7.3) 32 (7.7) 237 (8.5) 414 (8.4) 18 (9.7) 2 (3.7) (8.3) 76 (8.6) 32 (7.7) 248 (8.9) 427 (8.7) 19 (10.3) 3 (5.6) 854 (100.0) 886 (100.0) 415 (100.0) 2,777 (100.0) 4,932 (100.0) 185 (100.0) 54 (100.0)

16 16 7. General Features of Primary Brain Tumors ( ) 1) Months from Onset to Treatment month no. month no. month no. month no. year no. <1M 2, , , < 1, , < , , < , < , , < , < , , , , , , ,281 2) Diagnostic Methods surgical specimen 58,819 (86.1) CSF cell culture 118 (0.2) X-ray, Isotope 143 (0.2) clinical signs, symptoms 177 (0.3) autopsy 166 (0.2) CT 3,296 (4.8) MRI 3,846 (5.6) others 425 (0.6) 1,291 (1.9) 68,281 (100.0) 3) Existence of Malignant Neoplasms of Other Organ none 65,044 (95.3) others 1,661 (2.4) CNS 627 (0.9) 949 (1.4) 68,281 (100.0) 4) Clinical Grading no clinical symptoms 5,658 (8.4) subjective complaints only 15,375 (22.8) focal signs 35,084 (52.1) intracranial hypertension 7,690 (11.4) disturbance of consciousness 3,069 (4.6) coma 377 (0.6) respiratory impairment 80 (0.1) 67,333 (100.0) 948

17 17 5) Multiplicity 6) Location : Supra or Infratentorial single 64,899 (95.6) supratentorial 45,284 (66.8) multiple 2,811 (4.1) infratentorial 14,728 (21.7) other 212 (0.3) supra- & infra- 2,145 (3.2) 67,922 (100.0) others 5,645 (8.3) ,802 (100.0) 479 7) Laterality 8) Location of Cerebral Hemispheric Tumors right 19,676 (29.1) nos 35,345 (73.4) left 19,894 (29.5) dorsal 2,142 (4.5) bilateral 5,197 (7.7) lateral 4,353 (9.1) central 19,450 (28.8) medial 5,597 (11.6) others 3,321 (4.9) ventoral 688 (1.4) 67,538 (100.0) 48,125 (100.0) 743 nos : not otherwise specified 2,211 9) Tumor Location (except Meningioma) frontal lobe 6,678 (13.6) pineal region 1,388 (2.8) tenporal lobe 3,673 (7.5) aqueduct 49 (0.1) parietal lobe 2,613 (5.3) cerebellar vermis 1,164 (2.4) occipital lobe 818 (1.7) cerebellar hemisphere 1,593 (3.2) diffuse 270 (0.6) fourth ventricle 660 (1.3) chiasmal region 11,191 (22.8) cerebello- pontine angle 6,927 (14.1) third ventricle, ant. 656 (1.3) caudal brain stem 1,170 (2.4) third ventricle, post. 187 (0.4) (pons and medulla) lateral ventricle 621 (1.3) optic nerve 206 (0.4) (ant. horn-body) calvarium 390 (0.8) lat. vent. (trigonum) 210 (0.4) skull base, medial 2,304 (4.7) lat. vent. (tenp. horn) 69 (0.1) skull base, paramedial 551 (1.1) corpus callosum and 583 (1.2) others 3,700 (7.5) septum pellucidum rostral brain stem and 1,457 (3.0) 49,128 (100.0) basal ganglia 1,208

18 18 10) Tumor Location on Meningioma parasagittal olfactory groove 626 (3.5) 1. anterior 1/3 675 (3.8) parasellar 2. middle 1/3 972 (5.5) 1. tuberculum sellae 987 (5.6) 3. posterior 1/3 385 (2.2) 2. planum sphenoidale 238 (1.3) 18 (0.1) 3. intrasellar 54 (0.3) falx 42 (0.2) 1. anterior 1/3 940 (5.3) middle fossa 441 (2.5) 2. middle 1/3 583 (3.3) ventricle 3. posterior 1/3 444 (2.5) 1. lateral v. 246 (1.4) 43 (0.2) 2. third v. 19 (0.1) convexity 3. fourth v. 13 (0.1) 1. frontal 2,537 (14.3) 2 (0.0) 2. temporal 537 (3.0) cerebello-pontine angle 1,166 (6.6) 3. parietal 1,154 (6.5) tentorium 1,315 (7.4) 4. occipital 234 (1.3) clivus 330 (1.9) 5. Sylvian fissure 49 (0.3) cerebellar convexity 404 (2.3) 40 (0.2) foramen magnum 193 (1.1) sphenoid ridge others 1,237 (7.0) 1. lateral 1/3 498 (2.8) 2. middle 1/3 418 (2.4) 3. medial 1/3 848 (4.8) 17,767 (100.0) 79 (0.4) ) Tumor Character of Growth 12) Infiltration to Other Tissue Out of Brain diffuse solid 15,825 (24.5) none 43,727 (69.3) cystic 2,844 (4.4) arachnoid 2,862 (4.5) circumscribed solid 38,519 (59.5) dura 8,939 (14.2) cystic 7,518 (11.6) skull 2,117 (3.4) 64,706 (100.0) scalp 115 (0.2) 3,575 not otherwise specified 5,303 (8.4) 63,063 (100.0) 5,218 13) Extracranial Metastases 14) Tumor Size : Diameter none 62,231 (97.5) <0.5cm 1,129 (1.9) spinal 1,284 (2.0) 1 7,148 (11.8) others 308 (0.5) 2 14,528 (24.0) 63,823 (100.0) 3 16,414 (27.1) 4, ,327 (17.0) 5 6,141 (10.1) 6 2,614 (4.3) (1.4) >8cm 1,491 (2.5) 60,623 (100.0) 7,658

19 19 8. Mode of Therapy ( ) 1) Operation first (%) second (%) none 10,516 (12.9) 45,901 (91.3) decompression 1,519 (1.9) 408 (0.8) biopsy or partial 9,240 (11.3) 470 (0.9) 50% resected 4,623 (5.7) 422 (0.8) 75% resected 10,667 (13.1) 938 (1.9) 95% resected 16,701 (20.5) 1,190 (2.4) removal 28,340 (34.7) 939 (1.9) 81,606 (100.0) 50,268 (100.0) 1, ) Radiotherapy RADIATION MODE none 53,767 (65.7) none 53,767 (65.9) irradiated 28,071 (34.3) external irradiation 26,539 (32.5) internal irradiation 185 (0.2) others 1,138 (1.4) 81,838 (100.0) 81,629 (100.0) 1,006 1,215 3) Mode of Irradiation Co 60 6,145 (22.6) Linac 20,276 (74.4) β-tron 57 (0.2) Heavy particle 24 (0.1) Isotope 47 (0.2) others 705 (2.6) 27,254 (100.0) 817 4) Radio-Sensitizer none 24,342 (90.9) BUdR 84 (0.3) others 70 (0.3) anticancer drug 2,296 (8.6) 26,792 (100.0) 1,279

20 20 5) Radiation to Spinal Cord none 25,758 (94.8) irradiated 1,418 (5.2) 27,176 (100.0) 895 6) Total Dose of Irradiation 0-10(Gy) 331 (1.2) 20 1,661 (6.2) 30 2,169 (8.1) 40 3,494 (13.1) 50 10,003 (37.4) 60 7,966 (29.8) (3.0) (0.5) 80< 192 (0.7) 26,747 (100.0) 1,324 7) Chemotherapy none 66,428 (81.5) done 15,041 (18.5) 81,469 (100.0) 1,375 8) Chemotherapeutic Agents ( ) chemotherapeutic agents first second third fourth Methotrexate 836 (5.7) 74 (0.9) 68 (2.6) 32 (5.6) 5-FU 577 (4.0) 154 (1.9) 29 (1.1) 8 (1.4) Endoxan 345 (2.4) 192 (2.3) 72 (2.7) 27 (4.7) MMC 145 (1.0) 81 (1.0) 28 (1.1) 2 (0.4) Vincristine 1,797 (12.3) 1,017 (12.4) 284 (10.7) 38 (6.6) BCNU 16 (0.1) 7 (0.1) 1 (0.0) - (-) CCNU 18 (0.1) 5 (0.1) 1 (0.0) 1 (0.2) Cyclocytidine 4 (0.0) 20 (0.2) 10 (0.4) 4 (0.7) Procarbazine 64 (0.4) 182 (2.2) 108 (4.1) 23 (4.0) Adriamycin 209 (1.4) 236 (2.9) 227 (8.5) 33 (5.7) Bleomycin 188 (1.3) 195 (2.4) 72 (2.7) 30 (5.2) Actinomycin-D 8 (0.1) 26 (0.3) 15 (0.6) 6 (1.0) Me-CCNU 13 (0.1) 4 (0.1) - (-) - (-) ACNU 5,888 (40.4) 1,503 (18.3) 237 (8.9) 22 (3.8) Tegafur 204 (1.4) 211 (2.6) 31 (1.2) 14 (2.4) Cisplatin 1,791 (12.3) 810 (9.9) 295 (11.1) 46 (8.0) MCNU 1,024 (7.0) 337 (4.1) 57 (2.1) 6 (1.0) VP (3.5) 1,353 (16.5) 229 (8.6) 61 (10.6) IFN-β 52 (0.4) 83 (1.0) 30 (1.1) 3 (0.5) others 882 (6.1) 1,719 (20.9) 873 (32.7) 221 (38.3) 14,571 (100.0) 8,209 (100.0) 2,667 (100.0) 577 (100.0)

21 21 9) Performance State: Before Treatment *1 32,205 (39.9) 2 20,952 (25.9) 3 7,953 (9.8) 4 11,451 (14.2) 5 4,120 (5.1) 6 3,526 (4.4) (0.7) 80,799 (100.0) 2,044 10) Performance State: After Treatment *1 38,307 (48.3) 2 16,319 (20.6) 3 7,353 (9.3) 4 8,160 (10.3) 5 2,773 (3.5) 6 2,879 (3.6) 7 3,546 (4.5) 79,337 (100.0) 2,710 * 1. Normal: No complaints; No evidence of disease 2. Normal activity with effort; some symptoms 3. Cares for self; Unable to carry on normal activity 4. Requires occasional assistance; Cares for most needs 5. Disabled; Requires special needs and assistance 6. Severely disabled; Hospitalized, death not imminent 7. Morbibund; Fatal processes are rapidly progressing 9. Unknown

22 22 9. General Features of Metastatic Brain Tumors ( ) 1) Age distribution of Metastatic Tumors age male (%) female (%) (%) 0 2 (0.0) 3 (0.1) 5 (0.0) 1 2 (0.0) 4 (0.1) 6 (0.0) 2 3 (0.0) 7 (0.1) 10 (0.1) 3 9 (0.1) 1 (0.0) 10 (0.1) 4 8 (0.1) 2 (0.0) 10 (0.1) (0.2) 14 (0.3) 30 (0.2) (0.1) 7 (0.1) 20 (0.1) (0.3) 12 (0.2) 34 (0.2) (0.4) 23 (0.4) 58 (0.4) (0.5) 40 (0.7) 84 (0.6) (0.8) 103 (1.9) 173 (1.2) (1.7) 212 (3.9) 367 (2.5) (3.7) 374 (6.8) 703 (4.9) (6.1) 569 (10.3) 1,118 (7.7) (9.7) 683 (12.4) 1,556 (10.7) ,310 (14.6) 724 (13.1) 2,034 (14.0) ,612 (18.0) 815 (14.8) 2,427 (16.8) ,658 (18.5) 725 (13.2) 2,383 (16.5) ,316 (14.7) 646 (11.7) 1,962 (13.6) (7.6) 382 (6.9) 1,061 (7.3) (2.5) 125 (2.3) 345 (2.4) (0.5) 34 (0.6) 76 (0.5) (0.0) 7 (0.1) 10 (0.1) (0.0) 1 (0.0) 2 (0.0) 8,971 (100.0) 5,513 (100.0) 14,484 (100.0) ) Months from Onset to Surgery 3) Diagnostic Methods <1M 1,234 (9.4) 18 7 (0.1) surgical specimen 9,845 (68.2) 1 6,855 (52.5) 19 7 (0.1) CSF cell culture 244 (1.7) 2 2,280 (17.5) (0.1) X-ray, Isotope 102 (0.7) (7.4) 21 1 (0.0) symptoms 36 (0.3) (3.6) 22 6 (0.1) autopsy 97 (0.7) (2.1) 23 4 (0.0) CT 2,498 (17.3) (1.9) (0.3) MRI 1,438 (10.0) (1.0) (0.2) others 175 (1.2) 8 62 (0.5) (0.2) 14,435 (100.0) 9 70 (0.5) (0.0) (0.5) (0.1) (0.2) (0.0) (0.9) (0.1) (0.1) (0.0) (0.3) (0.2) (0.1) (0.1) 13,066 (100.0) 17 5 (0.0) 1,497

23 23 4) Months from Diagnosis of Primary Tumor to Diagnosis of Metasitatic Brain Tumor <1M 2,222 (20.3) (1.6) (3.4) (7.5) (1.5) (1.3) (3.0) (1.1) (2.7) (2.5) (1.0) (0.7) (2.7) (1.4) (2.0) (2.4) (0.9) (0.4) (3.3) (1.1) (1.4) (2.3) (0.6) (0.3) (2.4) (0.9) (0.7) (2.0) (0.6) (3.9) (2.3) (3.8) (1.7) (4.1) (4.2) (4.6) 10,929 (100.0) (1.4) (2.3) 3,634 5) Clinical Grading no symptoms 650 (4.5) complaints omly 1,434 (10.0) focal signs 8,482 (59.0) increased ICP 2,582 (18.0) disturbance of consciousness 1,028 (7.2) coma 188 (1.3) respiratory impairment 23 (0.2) 14,387 (100.0) 176 6) Recurrence of Primary Tumor at The Time of Diagnosis of Metastatic Brain Tumor recurrence(-) 5,959 (57.3) recurrence(+) 4,444 (42.7) 10,403 (100.0) 4,160 7) Metasta sis to Other Organs metastasis(-) 6,454 (56.3) metastasis(+) 5,005 (43.7) 11,459 (100.0) 3,104

24 24 8) Mode of Metastasis 11) Location of Metastasis solitary 8,614 (59.6) frontal lobe 2,415 (17.4) multiple 5,450 (37.7) temporal lobe 728 (5.3) mening. ca. 401 (2.8) parietal lobe 1,616 (11.6) 14,465 (100.0) occipital lobe 949 (6.8) 98 diffuse 31 (0.2) chiasmal region 53 (0.4) third ventricle, ant. 15 (0.1) third ventricle, post. 12 (0.1) 9) Location : Supra or Infratentorial lateral ventricle 33 (0.2) (ant.horn-body) supratentorial 9,504 (66.0) lat. vent. (trigonum) 27 (0.2) infratentorial 2,059 (14.3) lat. vent. (temp.horn) 93 (0.7) supra- & infratentorial 2,227 (15.5) corpus callosum and 152 (1.1) others 613 (4.3) septum pellucidum 14,403 (100.0) rostral brain stem 218 (1.6) 160 and basal ganglia pineal region 45 (0.3) aqueduct 5 (0.0) cerebeller vermis 307 (2.2) 10) Laterallity cerebellar hemispher 1,300 (9.4) fourth ventricle 21 (0.2) right 4,578 (32.0) cerebello-pontine angle 101 (0.7) left 4,459 (31.2) caudal brain stem 59 (0.4) bilateral 3,166 (22.2) (pons and medulla) central 780 (5.5) optic nerve 14 (0.1) not otherwise specified 1,312 (9.2) calvarium 270 (2.0) 14,295 (100.0) skull-base, medial 182 (1.3) 268 skull-base, paramedial 183 (1.3) others 5,050 (36.4) 13,879 (100.0) 684

25 25 12) Frequency of Tumors by Primary Cancer 15) Mode of Operation for Primary Cancer lung 6,947 (51.9) none 6,448 (48.8) breast 1,246 (9.3) radical 5,292 (40.1) homatopoietic 55 (0.4) non-radical 1,469 (11.1) bone 85 (0.6) 13,209 (100.0) soft tissue 80 (0.6) 1,354 skin 136 (1.0) stomach 646 (4.8) intestine 627 (4.7) 16) Histological Diagnosis of Metastatic rectum 726 (5.4) Brain Tumors liver 278 (2.1) spleen 10 (0.1) adeno 7,394 (59.3) head and neck 433 (3.2) squamous 1,615 (13.0) thyroid 192 (1.4) undifferentiated 150 (1.2) testis 74 (0.6) oat(small) cell 765 (6.1) bladder 101 (0.8) transitional 96 (0.8) uterus 226 (1.7) AML 10 (0.1) ovary 120 (0.9) ALL 16 (0.1) kidney 715 (5.3) CML 3 (0.0) eye 30 (0.2) CLL 2 (0.0) lymph node 96 (0.7) other L 11 (0.1) nervous tissue 31 (0.2) sarcoma 173 (1.4) others 539 (4.0) retinoblastoma 10 (0.1) 13,393 (100.0) neuroblastoma 31 (0.3) 1,170 melanoma 182 (1.5) lymphoma 211 (1.7) clear cell 386 (3.1) 13) Mode of Treatment for Primary Cancer large cell 424 (3.4) others 985 (7.9) none 3,895 (28.3) 12,464 (100.0) ope, rad, chem 1,620 (11.8) 2,099 ope, rad 662 (4.8) ope, chem 2,401 (17.5) rad, chem 676 (4.9) ope 2,785 (20.3) rad 457 (3.3) chem 1,134 (8.2) others 126 (0.9) chem : chemotherapy 13,756 (100.0) ) Hormonal Treatment for Primary Cancer none 12,647 (96.1) oophorectomy 59 (0.5) adrenalectomy 6 (0.1) hypophysectomy 4 (0.0) steroid 207 (1.6) others 235 (1.8) 13,158 (100.0) 1,405